Merck Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III KEYNOTE-775/Study 309 trial for the Treatment of Advanced Endometrial Cancer at SGO

Shots:

• The P-III KEYNOTE-775/Study 309 trial involves assessing Keytruda (200mg, IV, q3w) + Lenvima (20mg, PO, qd) vs CT Doxorubicin (60 mg/m2, IV, q3wks.) or Paclitaxel (80 mg/m2, IV, 28-day cycle) in a ratio (1:1) in patients with advanced EC following one prior Pt -based regimen in any setting
• Results: 1EPs in all-comer population @ Median follow-up 11.4 mos., 44% reduction in the risk of disease progression or death; median PFS (7.2 vs 3.8 mos)., 38% reduction in the risk of death; median OS (18.3 vs 11.4 mos.)
• In the pMMR subgroup, 40% reduction in the risk of disease progression or death; median PFS (6.6 vs 3.8 mos); 32% reduction in the risk of death; median OS (17.4 vs 12mos.)

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Law.com